Ann: Promising Interim Results from TAVR Animal Study, page-44

Admedus has some great science/IP, perhaps the TAVR potentially the jewel in the Crown.

Unfortunately what has shackled this company, imo, till this time, imo, has been the failure to successfully ‘sell’ the science in a timely manner with failure to do so resulting massive cash burn, CRs, dilution and poor market sentiment as a result.

Encouraging announcement yet only a few pips sp movement to show for it, for the present! 


Sincerly hope that Admedus have learnt valuable lessons from bringing to market the Cardiocel IP, (a lesson that has cost investors dearly) and the failure to find partner for vaccine R&D early on.

Partner to cover R&D for TAVR should be a much shorter experience, imo, potential partner definitely in the ‘drivers seat’, guess we will never know if there are ‘rival’ bidders, you would hope so!

Lesson learnt too late to benefit current holders?


Worrying that sp continues to lanquish despite two conerstone ‘bookend’ investors, TAVR progressing and increasing revenue.

Admedus may need to convince the market that CRs are a thing of its ‘ugly’ past, that cash burn will not continue to blow out and the ‘presence’ of SB and SIO will be beneficial for retail investors.

Absolute disaster meanwhile that this company sits at less than half a cent pre-consolidation sp.